1. Home
  2. SNDR vs ABVX Comparison

SNDR vs ABVX Comparison

Compare SNDR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Schneider National Inc.

SNDR

Schneider National Inc.

HOLD

Current Price

$35.88

Market Cap

6.5B

Sector

Industrials

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$96.87

Market Cap

7.2B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNDR
ABVX
Founded
1935
2013
Country
United States
France
Employees
N/A
69
Industry
Trucking Freight/Courier Services
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
7.2B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
SNDR
ABVX
Price
$35.88
$96.87
Analyst Decision
Hold
Buy
Analyst Count
13
13
Target Price
$27.83
$131.31
AVG Volume (30 Days)
1.1M
2.8M
Earning Date
04-30-2026
03-23-2026
Dividend Yield
1.32%
N/A
EPS Growth
N/A
N/A
EPS
0.12
N/A
Revenue
$5,674,300,000.00
N/A
Revenue This Year
$5.11
$52.14
Revenue Next Year
$6.05
$4,132.27
P/E Ratio
$301.75
N/A
Revenue Growth
7.25
N/A
52 Week Low
$20.11
$7.41
52 Week High
$39.27
$148.83

Technical Indicators

Market Signals
Indicator
SNDR
ABVX
Relative Strength Index (RSI) 53.37 43.75
Support Level $26.88 $87.60
Resistance Level $39.27 $98.59
Average True Range (ATR) 1.26 7.37
MACD -0.42 -0.07
Stochastic Oscillator 23.46 71.13

Price Performance

Historical Comparison
SNDR
ABVX

About SNDR Schneider National Inc.

Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, LTL carriers, railroads, ocean carriers, airlines to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload, Intermodal, Logistics and other. It generates maximum revenue from the Truckload segment.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: